Mount Sinai blood and marrow transplant consortium
BMT CTN Core - Mount Sinai Consortium
This program brings together major transplant centers to improve prevention and treatment of acute graft-versus-host disease for children and adults who receive allogeneic bone marrow or stem cell transplants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11167732 on NIH RePORTER |
What this research studies
This consortium links Mount Sinai, Vanderbilt, and the Mayo Clinic to run clinical trials and share patient data across high-volume transplant centers. They use a large natural history database (MAGIC) of over 6,000 patients and blood biomarkers to identify who is most at risk for severe acute GVHD and who might respond to treatments. The team tests treatments including mesenchymal stromal cells (like remestemcel-L) for patients whose acute GVHD does not respond to steroids and builds multi-center trials to enroll large numbers quickly. They also include work on transplants for non-malignant diseases such as sickle cell disease to broaden who can benefit.
Who could benefit from this research
Good fit: Ideal candidates are children or adults undergoing or recently having an allogeneic hematopoietic cell (bone marrow or stem cell) transplant who are at risk for or have developed acute GVHD.
Not a fit: People who are not undergoing an allogeneic transplant, who only have chronic GVHD, or who have conditions unrelated to transplant are unlikely to be enrolled or benefit directly.
Why it matters
Potential benefit: Could lead to better tests to predict severe GVHD and new treatments that improve survival and recovery for patients with steroid-refractory acute GVHD.
How similar studies have performed: Some existing therapies like ruxolitinib help many patients and early work on biomarker-guided care and MSC (mesenchymal stromal cell) treatments has been promising, but steroid-refractory acute GVHD remains difficult to treat.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Levine, John — Icahn School of Medicine at Mount Sinai
- Study coordinator: Levine, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.